This is a very confident announcement, as it looks like IMU are directly going after Herceptin. The study is targeting patients who have progressed after treatment with Trastuzumab (Herceptin) and if this works Herceptin is effectively dead in the water, including any "bio similar" that is planning to come into the market. I suspect that this confidence comes from the data from our current phase one. I'm not sure that Genentic will risk waiting for results, very interesting 2022 coming up
All in my opinion Capt
This is a very confident announcement, as it looks like IMU are...
-
- There are more pages in this discussion • 152 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 4.9¢ | 4.8¢ | $328.5K | 6.792M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 45 | 5443565 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 2171910 | 5 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |